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The Expression of Epidermal Lipoxygenases and
Transglutaminase-1 Is Perturbed by NIPAL4
Mutations: Indications of a Common Metabolic
Pathway Essential for Skin Barrier Homeostasis
Hao Li1, Elizabeth P. Lorie`1, Judith Fischer2, Anders Vahlquist1 and Hans To¨rma¨1
Autosomal recessive congenital ichthyosis (ARCI) is a heterogeneous group of skin barrier diseases due inter
alia to mutations in transglutaminase-1 (TGM1), in lipoxygenases (LOXs) of the hepoxilin pathway, and in
ichthyin, a putative Mg2þ transporter encoded by the NIPAL4 gene. In search of a common pathogenic pathway
for ARCI, we investigated the epidermal expression of TGM1, 12R-LOX, eLOX-3, and ichthyin in skin biopsies
from four healthy controls and nine patients with ARCI. In healthy skin, TGM1, ichthyin, and the LOX enzymes
were predominantly expressed in the upper epidermis where colocalization signals could also be demonstrated
by in situ proximity ligation assay. In patients with ALOX12B mutations and abnormal 12R-LOX expression, the
colocalization signal for eLOX-3 and TGM1 was increased 4-fold. In contrast, patients with NIPAL4 mutations and
abnormal ichthyin expression showed increased 12R-LOX and eLOX-3 staining and a colocalization signal of
these LOXs that was three times the normal intensity. Treatment of these patients with a retinoid-mimetic drug,
liarozole, normalized the expression of 12R-LOX and attenuated the colocalization signal. Altogether, our data
indicate that ichthyin and TGM1 are functionally closely related in the lipid processing and that this metabolic
pathway can be modified by retinoids.
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INTRODUCTION
Autosomal recessive congenital ichthyosis (ARCI) is a
group of rare diseases with an estimated prevalence of
1:200,000–300,000, affecting the cornification of the epider-
mis (Oji and Traupe, 2006). The clinical features include
thick scaling over large areas of the body surface together
with different degrees of erythroderma (Akiyama et al., 2003).
Patients are often born as collodion babies, which may be
self-improving (Vahlquist et al., 2010) or transform into
lamellar ichthyosis or ichthyosiform erythroderma (Oji et al.,
2010). ARCI is caused by mutations in several different genes,
including transglutaminase-1 (TGM1), ALOX12B, ALOXE3,
CYP4F22, ABCA12, SLC27A4/FATP4, and NIPAL4 (Lefe`vre
et al., 2004, 2006; Eckl et al., 2005; Akiyama, 2006; Herman
et al., 2009; Klar et al., 2009). Recently, TGM1 was found to
catalyze the covalent coupling of long-chain o-hydroxycer-
amides to the cornified envelope (Nemes et al., 1999; Elias
et al., 2002; Zheng et al., 2011). Several of the other genes
encode proteins that are involved in either epidermal lipid
transport or in the 12-lipoxygenase (LOX) (hepoxilin) path-
way, which converts the essential fatty acid arachidonic acid
present on all cell membranes into specific epoxyalcohols
essential for epidermal barrier homeostasis (Eckl et al., 2005;
Hall et al., 2005; Lefe`vre et al., 2006; Milger et al., 2006; Zuo
et al., 2008; Nilsson et al., 2010). It was also recently shown
that linoleic acid esterified to o-hydroxylacyl-sphingosine
might be a target for epidermal enzymes 12R-LOX and
eLOX-3 (Zheng et al., 2011). 12R-LOX can also convert
arachidonic acid into 12R-hydroperoxyeicosa-5,8,10,14-tet-
raenoic acid, which is further metabolized into hepoxilins by
eLOX-3 (Yu et al., 2003).
ALOX12B and ALOXE3 are both located on chromosome
17p13.1 (Lesueur et al., 2007), and the corresponding gene
products 12R-LOX and eLOX-3 are functionally closely
related. Their amino-acid sequences show 54% identity and
have a characteristic segment of 41 amino-acid residues,
suggesting that both enzymes are members of the same
structural class of LOXs (Kinzig et al., 1999). Indeed, the two
enzymes seem to operate in sequence in such a way that the
product of 12R-LOX is the preferred substrate of eLOX-3
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regardless of whether the substrate is 12R-hydroperoxyeico-
sa-5,8,10,14-tetraenoic acid or linoleate occurring in O-
linoleoyl-o-hydroxyceramide (Yu et al., 2003, 2006; Zheng
et al., 2011).
Compared with the LOX enzymes, much less is known
about the function of ichthyin, which is a granular layer
protein (Wajid et al., 2010) encoded by the NIPAL4 gene
(Lefe`vre et al., 2004). Ichthyin has several transmembrane
domains, showing homologies to both G-protein-coupled
receptors (Lefe`vre et al., 2004) and magnesium transporter
proteins (Lefe`vre et al., 2004; Quamme, 2010). However,
ichthyin is also proposed to be a membrane receptor for
trioxilins A3 and B3 produced by the hepoxilin pathway
(Lefe`vre et al., 2004). Mutations in NIPAL4 are associated
with abnormal lamellar bodies and perinuclear elongated
membranes in stratum granulosum typically found in ARCI of
EM type III (Dahlqvist et al., 2007). But exactly how ichthyin
functions in relation to lipid homeostasis and LOX expression
is uncertain, as is the epidermal distribution of the proteins in
normal and ARCI-affected skin.
Despite vast knowledge about the etiology of ARCI, only
few treatment options are available, none of which is disease
specific. Besides emollients and keratolytic agents, topical or
systemic vitamin A analogs (retinoids) are commonly used
(DiGiovanna and Robinson-Bostom, 2003; Vahlquist et al.,
2008). Liarozole and other retinoic acid metabolism–blocking
agents (RAMBAs) have also been reported to improve ARCI
(Verfaille et al., 2008; Pavez Lorie` et al., 2009), again
emphasizing the usefulness of retinoic acid receptor stimula-
tion in the treatment of ARCI. Interestingly, retinoid receptor
knockout mice exhibit ultrastructural abnormalities of lamel-
lar granules, which resemble certain types of ARCI (Calleja
et al., 2006). Yet, the exact mechanism by which retinoids
affect ARCI is unknown.
To obtain new insight into the homeostatic regulation of
the hepoxilin pathway and its response to ichthyin mutations
and retinoid therapy, we decided to study the interplay
between 12R-LOX, eLOX-3, and ichthyin expression in the
epidermis from patients with various forms of ARCI, some of
who were treated with RAMBA. The results show inter alia
colocalization of 12R-LOX and eLOX-3, which was en-
hanced by inactivating ichthyin mutations and could be
counteracted by retinoid stimulation.
RESULTS
Immunofluorescence staining of TGM1, 12R-LOX, eLOX-3, and
ichthyin in normal versus diseased skin
TGM1. In healthy control skin, TGM1 was found at the cell
borders of the granular layer (Supplementary Figure S1a
online). A similar expression pattern was seen in patients with
mutations in TGM1 (compound heterozygous for the missense
mutations p.Ser358Arg and p.Val379Leu (Supplementary
Figure S1e online) or compound heterozygous for the acceptor
splice site/missense combination of mutations c.877-2A4G
and p.Val379Leu (data not shown)) and in ALOXE3 (com-
pound heterozygous for the donor splice site mutations
c.1305þ 1G4T and c.1305þ 2A4T (Supplementary Figure
S1c online) or missense mutations p.Arg234X and p.Pro630-
Leu (data not shown)). In patients with mutations in ALOX12B
(homozygous for the missense mutation p.Gly462Asp (Sup-
plementary Figure S1b online) or compound heterozygous for
the missense mutations p.Pro422Leu and p.Tyr521Cys (data
not shown)) and NIPAL4 (three patients homozygous for the
missense mutation p.Ala176Asp (Supplementary Figure S1d
online)), the TGM1 expression was increased compared with
control skin and extended into the stratum corneum. In
addition, all patients (independent of mutation type) showed
TGM1 expression also extending into the spinous layer
(Supplementary Figure S1b–S1e online).
Lipoxygenases. 12R-LOX was predominantly expressed in the
basal and granular layers of healthy skin (Figure 1a). In the
patients with ALOX12B missense mutations, the protein
expression was markedly decreased in the entire epidermis
(Figure 1b). By contrast, 12R-LOX was expressed throughout
the entire epidermis in patients with ALOXE3, NIPAL4, and
TGM1 mutations (Figure 1c–e), and a re-localization to cell
nucleus was found in most of these patients. Color versions of
Figures 1–6 are found in the Supplementary Material online.
In contrast to 12R-LOX, eLOX-3 was uniformly expressed
throughout the epidermis, especially in viable layers of healthy
control skin (Figure 2a). The accentuated staining along the
cell borders implies that eLOX-3 is a component of the cell
membranes. In patients with ALOX12B, ALOXE3, and TGM1
mutations, a slightly increased staining of eLOX-3 was found
(Figure 2b, c, and e). In patients with NIPAL4 mutations,
eLOX-3 expression extended throughout the epidermis, with a
clear staining also noticed in the stratum corneum (Figure 2d).
Ichthyin. In healthy control skin, same as in a patient with
TGM1 mutations, ichthyin was expressed in the viable portion
of the epidermis, with highest expression found in granular
layers, and the protein was localized to the cell borders in a
honeycomb pattern (Figure 3a and e). In patients with
ALOX12B or ALOXE3 mutations, the ichthyin expression
showed a similar distribution but was slightly increased
compared with control skin (Figure 3b and c). By contrast, in
the three patients homozygous for NIPAL4 missense muta-
tions, the protein was found not only in the cell periphery but
also in the cytoplasm of the upper viable epidermis (Figure
3d). When analyzing transmembrane helices of the protein
sequences of wild-type and mutated ichthyin using TMHMM
2.0, an outside-to-inside switch of the N-terminal domain was
predicted for the mutated protein.
Colocalization of 12R-LOX and eLOX-3 in healthy and
diseased epidermis
The two LOXs were recently shown to be functionally related
in two separate epidermal pathways (Yu et al., 2007; Zheng
et al., 2011). To study a possible physical interaction between
the two enzymes in the stratum granulosum, in situ proximity
ligation assay (PLA) was used, which detects a close proximity
(o30–40 nm) of analyzed proteins (So¨derberg et al., 2008). In
healthy control skin, distinct 12R-LOX and eLOX-3 coloca-
lization signals were mainly found in the stratum granulosum,
although some positive signals were also found in the lower
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stratum spinosum (Figure 4a). Similar PLA signal levels were
detected in patients with ALOX12B, ALOXE3, and TGM1
mutations (Figure 4b, c, and e). However, in patients with
NIPAL4 mutations, the signals were distributed throughout
the epidermis, with the highest-intensity signals seen in the
stratum corneum (Figure 4d). This difference was confirmed
by counting the signals (blobs), showing a 3-fold higher
colocalization signal increase in patients with NIPAL4
mutations as compared with both healthy controls and
patients with ALOX12B and TGM1 mutations (Figure 4f). In
contrast, signals were 50% lower in patients with ALOXE3
mutations compared with healthy controls.
To confirm that the in situ PLA signals indeed reflected a
colocalization of 12R-LOX and eLOX-3, we used an
independent method, immuno-coprecipitation followed
by immunoblotting, to detect the two enzymes in
extracts of normal epidermis. By this approach, both eLOX-3
and 12R-LOX were detected as 80-kDa bands in
the immunoprecipitate produced with a 12R-LOX antibody
(Supplementary Figure S6 online), verifying a physical inter-
action between the two enzymes in real life.
Colocalization of eLOX-3 and 12R-LOX with TGM1
in healthy and diseased epidermis
By using in situ PLA, we further analyzed whether eLOX-3
and 12R-LOX colocalized with TGM1 in the epidermis. In
healthy control skin, distinct signals representing eLOX-3 and
TGM1 colocalization were mainly found in the upper stratum
a b c
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Figure 1. 12R-lipoxygenase (LOX) is expressed in normal epidermis and is upregulated in patients with NIPAL4 mutations. Immunofluorescence staining
showed that 12R-LOX was expressed predominantly in the basal and granular layer of healthy skin (a). 12R-LOX expression in an autosomal recessive congenital
ichthyosis (ARCI) patient homozygous for the missense mutation p.Gly462Asp in ALOX12B was depressed but not completely lacking, (b) and increased in a
patient who was compound heterozygous for the splice-site mutations c.1305þ 1G4T and c.1305þ 2A4T in ALOXE3 (c). More intensive staining in the
spinous and granular layer, as well as in stratum corneum, was found in patients who were homozygous for the missense mutation p.Ala176Asp in NIPAL4 (d)
and compound heterozygous for the missense mutations p.Ser358Arg and p.Val379Leu in transglutaminase-1 (TGM1) (e). The stainings are also representative of
those of the other ARCI patients, which are not included in this figure (see Materials and Methods section for mutations in these patients). Staining of healthy
control skin with control IgG from same species was negative (f). Scale bars represent 20 mm. s.b., stratum basale; s.c., stratum corneum.
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Figure 2. eLOX-3 is expressed throughout the epidermis and is upregulated in patients with NIPAL4 mutations. Immunofluorescence staining showed that
eLOX-3 was expressed in a membranous honeycomb-like pattern in all viable layers of healthy skin (a). The staining is slightly increased in patients with
ALOX12B (b) and ALOXE3 mutations (c). eLOX-3 was additionally expressed in the stratum corneum in patients with NIPAL4 mutations (d), whereas it remained
unchanged in patients with transglutaminase-1 (TGM1) mutations (e). Patients shown are the same ones as in Figure 1. Staining of healthy control skin with
control IgG from the same species was negative (f). Scale bars represent 20 mm. s.b., stratum basale; s.c., stratum corneum.
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granulosum and lower stratum corneum, although some
positive signals were also found in the lower stratum
spinosum (Figure 5a, Supplementary Figure S8 online). In
patients with ALOX12B or ALOXE3 mutations (Figure 5b and
c), more PLA signals, also localized to the lower strata, were
seen. However, in patients with TGM1 mutations, the
signals were sparse and mainly found in the stratum corneum
(Figure 5e). By contrast, the signals in patients with NIPAL4
mutations were distributed throughout the entire epidermis
(Figure 5d).
In healthy control skin and in patients with NIPAL4
mutations, distinct signals representing 12R-LOX and TGM1
colocalization were mainly found in the upper stratum
granulosum and lower stratum corneum, although some
positive signals were also found in the lower stratum
spinosum (Supplementary Figure S9a and S9d online).
Slightly increased PLA signal levels were detected in patients
with ALOX12B (Supplementary Figure S9b online) mutations,
whereas this was unchanged in patients with ALOXE3
(Supplementary Figure S9c online). However, in patients
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Figure 3. Altered ichthyin protein expression in NIPAL4-mutated skin versus healthy skin and other forms of autosomal recessive congenital ichthyosis
(ARCI). Representative immunostainings of ichthyin showed expression in the entire viable epidermis of the healthy skin, and the localization was restricted to
cell membranes (a). More intense staining was found in patients with ALOX12B and ALOXE3 mutations (b, c). Decreased intensity and altered localization were
noticed in patients with mutations in NIPAL4. The expression in the lower viable layers was normal, but was altered in the upper layers (d). The staining in
patients with transglutaminase-1 (TGM1) mutations was normal (e). Staining of healthy control skin with control IgG from same species was negative (f). Scale
bars represent 20mm. (See Supplementary Material online for Figures 1–6 in color.) s.b., stratum basale; s.c., stratum corneum.
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Figure 4. Colocalization signal of 12R-lipoxygenase (LOX) and eLOX-3 is increased in patients with NIPAL4 mutations. DuoLink in situ proximity
ligation assay showed a colocalization of 12R-LOX and eLOX-3 mainly in the stratum spinosum up to the upper granular layer in healthy control skin
(a). The colocalization is not changed in patients with ALOX12B mutations (b), whereas it is reduced in patients with ALOXE3 mutations (c). Intensity
and number of signals (blobs) are markedly increased in the entire epidermis and especially in the stratum corneum of patients with NIPAL4 mutations
(d). The signal intensity in patients with transglutaminase-1 (TGM1) mutations was similar to that of control skin (e). Semiquantitative image analysis shows
a 3-fold increase in signals in patients with NIPAL4 mutations (f). The data in (f) are expressed as colocalization signals (mean±SD). Scale bars represent 20 mm.
Dotted lines indicate s.c., stratum corneum and s.b., stratum basale. NS, non-significant. *Po0.05.
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with TGM1 mutations the signals were sparse and mainly
found in the stratum corneum (Supplementary Figure S9e
online). The average number of colocalization signals
between 12R-LOX and TGM1 was much lower than that of
eLOX-3 and TGM1.
Regulation of 12R-LOX/eLOX-3 co-expression by RAMBA
treatment
For this purpose, we used skin biopsies from a previous study,
which examined the effects of oral liarozole in lamellar
ichthyosis, showing inter alia that patients with NIPAL4
mutations seemed to respond better to therapy than patients
with TGM1 mutations (Pavez Lorie` et al., 2009). When the
expression of 12R-LOX and eLOX-3 was investigated in
patients with NIPAL4 mutations, a reduced stratum corneum
staining was found for both proteins after liarozole treatment
(Figure 6a–d), and the increased colocalization signal was
normalized (Figure 6e). In line with this, the increased
baseline mRNA expression of ALOX12B in patients with
NIPAL4 mutations decreased upon liarozole treatment
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Figure 5. eLOX-3 and transglutaminase-1 (TGM1) colocalization is increased in patients with ALOX12B and ALOXE3 mutations. Colocalization of eLOX-3
and TGM1 was found mainly in the granular layer of healthy control skin (a). The colocalization was markedly increased in patients with ALOX12B (b) and
ALOXE3 mutations (c), whereas it remained unchanged in patients with NIPAL4 (d) and TGM1 mutations (e). Semi-quantitative image analysis shows an
increase in eLOX-3 and TGM1 colocalization in patients with ALOX12B and ALOXE3 mutations (f). The data in (f) are expressed as colocalization signals
(mean±SD). Scale bars represent 20 mm. Dotted lines indicate s.c., stratum corneum and s.b., stratum basale. NS, non-significant. *Po0.05, **Po0.01.
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Figure 6. The enhanced colocalization of eLOX-3 and 12R-lipoxygenase (LOX) in patients with NIPAL4 mutations is mitigated by liarozole therapy. Biopsies
were obtained from two patients with NIPAL4 mutations before (a, c) and after a 1-month treatment with 75 mg liarozole per day (b, d). Sections were stained by
immunofluorescence for detection of 12R-LOX (a, b) and eLOX-3 (c, d) and by in situ PLA for eLOX-3/12R-LOX colocalization studies using the DuoLink Image
Tool (e). At baseline, the patients showed a 3-fold increase in colocalization signals, which was reduced after liarozole treatment. Scale bars represent 20 mm.
The mRNA expression of ALOX12B was increased in the patients at baseline as compared with healthy control skin but was normalized upon liarozole
treatment. By contrast, ALOXE3 was expressed at similar levels as in healthy skin at baseline and after treatment (f). The data in (e) are expressed as
colocalization signals (mean±SD). NS, non-significant; PLAS, proximity ligation assay; s.b., stratum basale; s.c., stratum corneum. **Po0.01.
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(Figure 6f). By contrast, the ALOXE3 mRNA expression,
which was similar in healthy control and NIPAL4-mutated
skin before therapy, was not affected by liarozole treatment
(Figure 6f), again implying that changes in the 12R-LOX/
eLOX-3 colocalization signals were entirely due to changes
in ALOX12B expression.
DISCUSSION
In this study, we detected the expression of 12R-LOX and
eLOX-3 in viable parts of healthy and ichthyotic epidermis,
extending to the stratum corneum in patients with NIPAL4
mutations. TGM1 was found to be variably expressed in the
upper viable epidermis in all ARCI patients. Furthermore, in
situ PLA showed a colocalization of 12R-LOX and eLOX-3 in
the stratum granulosum and lower stratum corneum of
healthy skin, and increased staining and colocalization
signals were found in biopsies from patients with NIPAL4
mutations. Whether this reflects a docking of the two
enzymes to a common substrate/product or a spatial coloca-
lization to membranous structures is currently unknown.
Similar interactions between lipid-metabolizing enzymes
have been reported previously. For example, stearoyl-
coenzyme A desaturase, the enzyme involved in the
desaturation of saturated fatty acids, has been shown to
colocalize with acyl-coenzyme A:diacylglycerol acyltransfer-
ase, the enzyme responsible for the final reaction in the
synthesis of triglycerides (Man et al., 2006). Furthermore, a
direct physical interaction between proteins may allow
certain lipids to be transported from one protein to another,
e.g., the translocation of retinoic acid to the nucleus involves
the interaction of cellular retinoic acid–binding protein II and
retinoic acid receptors, and during fat oxidation the transport
of fatty acids to carnitine palmitoyltransferase I involves fatty
acid translocase (FAT/CD36) (Budhu and Noy, 2002; Schenk
and Horowitz, 2006).
The present data on the distribution and colocalization of
LOXs in normal and diseased epidermis support the fact that
these enzymes work together either in the oxygenation of
ceramides (Zheng et al., 2011) or in the hepoxilin pathway.
The latter pathway includes a colocalization with ichthyin
and downstream activation of its function. Ichthyin was
detected in the entire epidermis of healthy subjects using two
different antibodies (recognizing the N terminus and C
terminus, respectively (for results see Figure 1 and Supple-
mentary Figure S1 online)). When the two antibodies were
diluted further, the protein expression was mainly found in
the granular layer (Supplementary Figure S2 online), which is
in agreement with the reported in situ location of the mRNA
(Wajid et al., 2010). In patients with NIPAL4 missense
mutations, we found an altered localization of ichthyin in the
epidermis and increased expression and colocalization of
12R-LOX and eLOX-3 (possibly by some kind of positive
feedback mechanism in response to a defective ichthyin
function), which was not the case in ARCI due to TGM1
mutations; this enzyme is not involved in the hepoxilin
pathway but catalyzes covalent coupling of lipids to the
cornified envelope (Zheng et al., 2011). The colocalization of
eLOX-3 and TGM1 is restricted to the stratum corneum,
despite the fact that eLOX-3 and TGM1 are expressed also in
the lower strata, which suggests that the two enzymes are
involved in covalent binding of acyl-ceramides to the
cornified lipid envelope. Furthermore, in subjects with
NIPAL4 mutations, the increased colocalization occurs in
the entire stratum corneum, suggesting that the 12R-LOX and
eLOX-3 enzymes do not have a normal turnover.
ARCI patients with mutations affecting the hepoxilin
pathway often respond particularly well to treatment with
synthetic retinoids (DiGiovanna and Robinson-Bostom,
2003; Vahlquist et al., 2008) or RAMBAs (Verfaille et al.,
2008; Pavez Lorie` et al., 2009). Retinoids alter the signaling
by direct binding to retinoic acid receptors, whereas RAMBAs
act by increasing the endogenous concentration of retinoic
acid. Previously, we showed that liarozole, when given orally
to patients with NIPAL4 mutations, markedly reduced the
ichthyosis score (Pavez Lorie` et al., 2009). In this study, we
continue to show that liarozole therapy specifically reduces
the elevated 12R-LOX mRNA and protein expression, and as
a consequence also normalizes the colocalization signals of
12R-LOX and eLOX-3 in patients with NIPAL4 mutations.
Hypothetically, this may contribute to the clinical efficacy of
liarozole and retinoid therapy in this condition, because
overexpression of 12R-LOX and eLOX-3 probably represents
a futile attempt to compensate for the intrinsic barrier defect
by excessive production of aberrant barrier lipids and horny
layer, i.e., the very hallmarks of ARCI. The mechanisms of
action of retinoids in the treatment of ARCI are not fully
understood. Assuming that Mg2þ is of importance for the
enzymes involved in the formation of cornified lipid
envelopes, it is tempting to speculate that retinoids upregu-
late other Mg2þ -transporter proteins besides ichthyin.
A further elucidation of the metabolic events leading to
hepoxilin-related ichthyosis and the impact of retinoid
stimulation may lead to a refined and tailored therapy for
different subtypes of ARCI.
MATERIALS AND METHODS
Patients
This study was approved by the Regional Ethical Review Board at
Uppsala University and conducted in conformity with the Declaration
of Helsinki Principles. After informed written consent and after
infiltrating the skin with 2 ml lidocaine-adrenalin, 3-mm punch
biopsies were obtained from lesional skin on the trunk of three
subjects with NIPAL4 mutations, two with ALOX12B mutations, two
with ALOXE3 mutations, and from two subjects with TGM1
mutations. Four healthy volunteers also contributed. The subjects
had the following recurrent substitutions and splice-site mutations:
NIPAL4 (homozygous for the missense mutation p.Ala176Asp)
(Dahlqvist et al., 2007), ALOX12B (homozygous for the missense
mutation(s) p.Gly462Asp or compound heterozygous for p.Pro422Leu
and p.Tyr521Cys) (Vahlquist et al., 2010), ALOXE3 (compound
heterozygous for the missense mutations p.Arg234X and p.Pro630Leu
or compound heterozygous for the donor splice site mutations
c.1305þ 1G4T and c.1305þ 2A4T) (Vahlquist et al., 2010; Pigg
et al., unpublished observation), and TGM1 (compound heterozygous
for the missense mutations p.Ser358Arg and p.Val379Leu or com-
pound heterozygous for the acceptor splice site/missense combination
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of mutations c.877-2A4G and p.Val379Leu) (Pigg et al., unpublished
observation). The subjects with NIPAL4 and TGM1 mutations were all
women, aged 29 to 60 years, with moderate-to-severe lamellar
ichthyosis (Ga˚nemo et al., 2003; Dahlqvist et al., 2007). The subjects
with ALOX12B mutations, one woman and one man, were 25 and 35
years of age, respectively, at the time of biopsy. They were both born as
collodion babies, but the skin phenotype markedly improved thereafter
especially in the latter patient, i.e., consistent with pleomorphic ichth-
yosis (Vahlquist, 2010). The subjects with ALOXE3 mutations were both
25- to 30-year-old men with mild-to-moderate symptoms consistent
with pleomorphic ichthyosis (Vahlquist, 2010). All subjects were
otherwise healthy and used only emollients at the site of skin biopsy.
Two of the subjects with NIPAL4 mutations were included in a
previous clinical study aiming at examining the effects of liarozole
on retinoid-induced biomarkers (Pavez Lorie` et al., 2009). Both
patients received an oral dose of 75 mg per day. Skin biopsies were
obtained at baseline and after 1 month of treatment.
Immunofluorescence
Patient and healthy skin biopsies were frozen, and later 6-mm
sections were acquired. Tissue sections were fixed in ice-cold
acetone for 5 minutes, air-dried, washed, and then blocked with
Background Sniper (Biocare Medical, Concord, CA) for 30 minutes
at room temperature. The specimens were incubated with 1:400
dilution of primary rabbit polyclonal anti-ichthyin, goat polyclonal
anti-12R-LOX, or rabbit polyclonal anti-eLOX-3 antibody (clones N-
12, C-20, and T-14, respectively, all obtained from Santa Cruz
Biotechnology (Santa Cruz, CA)), at 4 1C overnight. After washing,
Alexa fluorophore–conjugated secondary antibody (Invitrogen,
Carlsbad, CA) was incubated at room temperature for 1 hour. The
slides were mounted using Vectashield mounting medium contain-
ing 40,6-diamidino-2-phenylindole (Vector Labs, Burlingame, CA)
and examined with an AxioImager Z1 microscope equipped with an
Apotome (Carl Zeiss AB, Stockholm, Sweden). Phosphate-buffered
saline was used for washing steps, and 2% BSA in phosphate-
buffered saline was used for dissolving the antibodies.
Immunoprecipitation, SDS-PAGE, and western blotting
12R-LOX was immunoprecipitated by incubating a lysate (1.5 mg
protein) from healthy skin with 4mg rabbit anti-12R-LOX antibody
(clone H-95, Santa Cruz Biotechnology) in a 400-ml reaction
overnight at 4 1C, followed by a 3-hour incubation with protein
A–agarose bead slurry (Santa Cruz Biotechnology). The beads were
washed three times with phosphate-buffered saline and proteins
solubilized in 2 SDS sample buffer before immunoblotting.
Proteins were separated on a 12.5% SDS-PAGE gel, transferred to
a nitrocellulose membrane, and detected using eLOX-3 (1:1,000,
clone T-14, Santa Cruz Biotechnology) and 12R-LOX (1:1,000, clone
H-95, Santa Cruz Biotechnology) antibodies as previously described
(Forsberg and Rollman, 2010).
Duolink in situ PLA
Using the DuoLink PLA kit and Duolink detection kit (Olink AB,
Uppsala, Sweden), we analyzed whether eLOX-3, 12R-LOX, and
TGM1 colocalized in the epidermis of healthy controls and in ARCI
patients. A positive colocalization is detected as a ‘‘blob’’. The signals
are formed by ligation and circulation of the proximity-bound probes,
synthesis of DNA by rolling-circle amplification of the circular DNA
template, followed by hybridization of fluorescence-labeled oligonu-
cleotides to the amplified DNA (So¨derberg et al., 2008). Briefly, 6-mm
tissue sections were acetone-fixed and exposed to Blocking solution
for 30 minutes at 37 1C. Goat polyclonal anti-12R-LOX (clone C-20,
Santa Cruz Biotechnology) and rabbit polyclonal anti-eLOX-3 (clone
T14, Santa Cruz Biotechnology) or mouse monoclonal anti-TGM1
(clone B.C1, Biomedical Technologies, Stoughton, MA) were diluted
1:200 and added to the sections, followed by incubation at 4 1C
overnight. Anti-goat probe MINUS and anti-rabbit probe PLUS/
MINUS or anti-mouse PLUS were diluted 1:10 and incubated at 37 1C
for 2 hours. Antibodies and probes were diluted in antibody diluent.
Hybridization, ligation, amplification, and detection step were
performed according to the manufacturers’ instructions (Olink AB).
Slides were mounted with Vectashield mounting medium containing
DAPI (Vector Labs) before being examined.
Image analysis of Duolink staining
Microphotographs were obtained using an AxioImager Z1 micro-
scope equipped with an EC Plan-Neofluar 40 objective. Two
sections from each patient were examined and totally five
consequent microphotographs were obtained from each section.
Duolink Image Tool software (Olink AB) was used for the
semiquantitative analysis of the signal, appearing as ‘‘blobs’’ in the
images. The entire epidermis was included in the analysis. Signal
size was set to 13 and signal threshold to 114 in the software. One-
way analysis of variance with Bonferroni’s multiple comparison test
was applied for statistics.
RNA isolation and complementary DNA synthesis
Total RNA was extracted from the cells and biopsies using Trizol
reagent (Invitrogen) and the concentration determined by UV
absorbance as described elsewhere (To¨rma¨ et al., 2006). First-strand
complementary DNA was synthesized from 3 mg of total RNA in a
30-ml reaction mixture containing oligo-d(T)15 primer and Moloney
murine leukemia virus reverse transcriptase (Invitrogen). After the
reaction, RNase-free water was added to a final volume of 60 ml.
Semiquantitative reverse-transcriptase–PCR
mRNA expression was quantified using 7500 Fast Real-Time PCR
system (Applied Biosystems, Carlsbad, CA). The 20-ml reaction
mixtures contained 20 ng complementary DNA and 0.2 mM primers
(Table S1 online) and Fast SYBR mixture (Applied Biosystems). The
PCR was performed for 40 cycles, each cycle consisting of 95 1C for
3 seconds and 60 1C for 30 seconds, followed by melt curve
stage. Relative gene expression was compared using the compa-
rative Ct (2DDCt) method, based on the assumption that the PCR
amplification efficiencies of the target and the reference genes are
similar to each other and approximately close to 100% (Livak and
Schmittgen, 2001).
Statistical analysis
Data analysis was performed by one-way analysis of variance
test with Bonferroni post-test using PRISM 5.0 (Graph Pad Software,
La Jolla, CA). Results are expressed as mean±SD. Statistical signi-
ficance was denoted * if Po0.05 and ** if Po0.01.
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